IL23R and Autoimmunity: Though there are no approved medications that target the interleukin-23 receptor, three interleukin-23 inhibitors or antagonists (i.e., ustekinumab, tildrakizumab, risankizumab) have been approved to treat autoimmune conditions including moderate-to-severe plaque psoriasis.97